Education and Training
Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD
The broad, long-term objective of the current research is to improve treatment outcomes for individuals with comorbid posttraumatic stress disorder (PTSD) and alcohol abuse and dependence (AUD).
The purpose of which is to evaluate changes in both PTSD symptoms and alcohol use and cravings associated with Cognitive Processing Therapy (CPT) or Relapse Prevention (RP) treatment in individuals with PTSD/AUD, along with mediators and moderators of outcomes.
The study will randomize 235 PTSD/AUD participants recruited from the VA and from the community to CPT, RP, or Interactive Voice Response (IVR) assessment only (AO). Those in the AO condition will be re-randomized after the treatment phase to either RP or CPT. Individuals will be assessed pretreatment, immediately post-treatment, 3-, 6-, 9-, and 12-months post-treatment and will monitor symptoms daily throughout treatment.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Cognitive Processing Therapy (CPT)
- behavioral: Relapse Prevention (RP)
Eligibility
Inclusion Criteria:
- Men and women age ≥ 18 years with a current DSM-V diagnosis of alcohol
abuse/dependence
- Recent alcohol consumption for at least 2 weeks in the past 30 day period OR at least
2 days of heavy drinking in the past 30 day period
- Desire to abstain from alcohol
- Current DSM-V (Diagnostic and Statistical Manual of Mental Disorders) diagnosis of
PTSD
- Capacity to provide informed consent
- English fluency
Exclusion Criteria:
- Men and women with an unstable psychiatric medication regimen
- Current trauma-focused mental health treatment (MH) or behaviorally focused alcohol
dependence (AD) AD/MH treatment in the past 30 days
- Suicide attempt or suicidal ideation with intent or plan, or self-harm in the past
month
- Presence of a psychotic disorder or uncontrolled Bipolar Disorder
- Signs or symptoms of alcohol withdrawal at the time of initial consent
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting